scholarly journals Comparative Analysis of Paper-based and Web-based Versions NFBSI-16 (National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index) Questionnaire in Breast Cancer Patients: Randomised, crossover study. (Preprint)

2020 ◽  
Author(s):  
Jinfei Ma ◽  
Zihao Zou ◽  
Emmanuel Eric Pazo ◽  
Feng Jin
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Chinese Language ◽  
Breast Cancer Patients ◽  
Systematic Treatment ◽  
Symptom Index ◽  
Web Based ◽  
Test Retest Reliability ◽  
Cancer Network ◽  
The Web

BACKGROUND Breast cancer remains the most common neoplasm diagnosed amongst women in China and globally. Health-related questionnaire assessments in research and clinical oncology settings have gained prominence. National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16) is a rapid and powerful tool to help evaluate the disease or treatment-related symptoms, both physical and emotional, in patients with breast cancer for clinical and research need. Prevalence of individual smartphones and social apps provide a potential electronic approach to administrating questionnaire; however, the reliability of NFBSI-16 in electronic format has not been assessed. OBJECTIVE This study aimed to assess the reliability of web-based measurement of NFBSI-16 in the Chinese language in breast cancer patients undergoing systematic treatment. METHODS We recruited patients with breast cancer under systematic treatment to complete both paper- and web-based questionnaires. Patients were randomly assigned to group A (paper- based first and web-based second) or group B (web- based first and paper-based second). A total of 354 patients included in the analysis successfully completed both versions of the NFBSI-16 questionnaire in Chinese language. Descriptive sociodemographic characteristics, reliability and agreement rates for single items, subscale, and total score were analyzed using Wilcoxon test. Lin’s concordance correlation coefficient (CCC), Spearman and Kendall tau rank correlation were used to assess test-retest reliability. RESULTS Test-retest reliability was excellent with CCCs 0.94 for the total NFBSI-16 score. Highly significant correlations were documented for all 4 subscales, 16 individual items, and total NFBSI-16 score. Mean differences of the test and re-test were all close to zero (≤0.06). A majority of the participants in this study preferred the web-based (72%, n=255) over the paper-based version. CONCLUSIONS The web-based version of the NFBSI-16 questionnaire is reliable for patients with breast cancer and demonstrated highly significant correlations with the paper-based version in all items, subscales and the total score. The web-based version of the NFBSI-16 questionnaire is an excellent tool for monitoring individual breast cancer patients under treatment, also as a majority of participants preferred it over paper-based version.

scholarly journals Feasibility of Providing Web-Based Information to Breast Cancer Patients Prior to a Surgical Consult

2017 ◽  
Vol 33 (5) ◽  
pp. 1069-1074 ◽  
Author(s):  
Jordan G. Bruce ◽  
Jennifer L. Tucholka ◽  
Nicole M. Steffens ◽  
Jane E. Mahoney ◽  
Heather B. Neuman
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Breast Cancer Patients ◽  
Web Based

Suggested modifications in the management of breast cancer patients in the era of COVID-19 pandemic: a web-based survey. (Preprint)

2021 ◽  
Author(s):  
Shereef Elsamany ◽  
Mohamed Elbaiomy ◽  
Ahmed Zeeneldin ◽  
Emad Tashkandi ◽  
Fayza Hassanin ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
United Arab Emirates ◽  
Hormonal Therapy ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Web Based ◽  
Cancer Management ◽  
Breast Cancer Management ◽  
Positive Breast Cancer

BACKGROUND Management of cancer patients in the current era of COVID-19 pandemic poses a significant challenge on health care systems. OBJECTIVE We explored the views of oncologists for the management of breast cancer patients during COVID-19 pandemic. METHODS A web-based questionnaire using SurveyMonkey was submitted to licensed oncologists involved in breast cancer management in Saudi Arabia, Egypt and United Arab Emirates. The survey focused on characteristics of participants, infection risk among cancer patients and possible treatment modifications related to different types of breast cancer RESULTS The survey was completed by 82 participants. For early HR positive, HER2-negative breast cancer,74.4% supported using neoadjuvant hormonal therapy in selected patients, and 58.0% preferred giving 6 over 8 cycles of adjuvant chemotherapy when indicated. Only 42.7% preferred CDK4/6 inhibitor with hormonal therapy as first line in all patients with metastatic HR-positive disease. 67.1% of participants supported using adjuvant trastuzumab for 6 instead of 12 months in selected patients with HER2-positive breast cancer. For metastatic HER2-positive, HR-positive breast cancer, 80.5% of participants supported the use of hormonal therapy with dual anti-HER2 blockade in selected patients. The preferred choice of 1st line treatment in metastatic triple negative patients with BRCA mutation and PDL1<1%, was PARP inhibitor according to 42.5% of the participants, and atezolizumab with nabpaclitaxel if the PDL1>1% according to 70.4% of the participants. CONCLUSIONS Several modifications in breast cancer management is supported by the survey participants. These modifications need to be discussed on local basis taking into account the local infrastructure and available resources. CLINICALTRIAL none

Prospective synoptic template recording to assess for compliance of care with NCCN guidelines for breast cancer.

2012 ◽  
Vol 30 (34_suppl) ◽  
pp. 197-197
Author(s):  
Titilayo Adegboyega ◽  
Jeffrey Landercasper ◽  
Jared Linebarger ◽  
Jeanne Johnson ◽  
Leah L. Dietrich ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Recognition ◽  
Performance Comparison ◽  
Molecular Profile ◽  
Breast Cancer Patients ◽  
Preoperative Testing ◽  
Nccn Guidelines ◽  
Real Time Analysis ◽  
Cancer Network

197 Background: There is a wide variation of compliance with National Comprehensive Cancer Network (NCCN) guidelines for diagnosis and treatment. Overutilization of preoperative testing and underutilization of adjuvant treatments have been documented. The former is associated with higher costs of care; the latter with poor patient outcomes. Prior reports of adherence to NCCN Guidelines contain methodological limitations due to lack of contemporary review and incomplete listing of reasons for non-compliance. This limits the “real time” analysis of breast cancer quality and delays action plans to address quality and cost issues of care. Methods: NCCN Guideline compliance was recorded prospectively by use of electronic synoptic templates for all newly diagnosed breast cancer patients treated at a single institution between January 2010 and December 2011. A retrospective review of the synoptic templates was then conducted. Accuracy of the synoptic auditing method was assessed as well as NCCN compliance and reasons for non-compliance. Results: A total of 312 new breast cancer patients who underwent surgery as initial treatment were identified. Compliance with NCCN Guidelines for preoperative testing, breast surgery and lymph node surgery was 98% (306/312), 99.7% (311/312) and 93% (290/312) respectively. Reasons for non-compliance include patient refusal, comorbidities, advanced age and overutilization of systemic imaging. There was 100% compliance to College of American Pathologist (CAP) molecular profile documentation for all breast cancer cases. There were two discrepancies noted between the prospective template reporting and medical record review. The average time needed to populate data into synoptic templates was less than 2 minutes per patient. Conclusions: Prospective auditing of adherence to NCCN Guidelines with electronic synoptic templates is accurate and time efficient. High compliance rates with NCCN Guidelines were demonstrated. Electronic synoptic NCCN templates potentially facilitate early recognition of quality gaps in compliance and provide a framework for peer performance comparison.

BRCA1/2 mutation prevalence among triple-negative breast cancer patients from a large commercial testing cohort.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1544-1544 ◽  
Author(s):  
Kristilyn Dillman Zonno ◽  
Rajesh R. Kaldate ◽  
Christopher Arnell ◽  
Jennifer Saam ◽  
Brian Abbott ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
African Ancestry ◽  
Parp Inhibitors ◽  
Ashkenazi Jewish ◽  
Breast Cancer Patients ◽  
Cancer Network ◽  
Testing Criteria

1544 Background: BRCA1/2 deleterious mutation identification among triple-negative breast cancer (TNBC) patients has gained importance due to cancer-risk management implications for patients and their relatives, and also has an emerging role in guiding treatment selection for therapies such as PARP inhibitors. The National Comprehensive Cancer Network (NCCN) currently recommends BRCA1/2 testing for TNBC patients diagnosed at age <60. Mutation prevalence among TNBC patients has previously been studied only in small regionalized cohorts. A recent study in unselected patients using the updated definitive criteria for TNBC reported mutation prevalence as 10.6%. Methods: Following the 2011 NCCN Hereditary Breast and Ovarian Cancer (HBOC) Testing Criteria update, serial cohorts of > 5,000 Ashkenazi Jewish and > 65,000 non-Ashkenazi Jewish breast cancer patients undergoing commercial BRCA1/2 testing were analyzed. Age at diagnosis, ethnicity, and provider-reported TN status were obtained from test requisition forms completed by ordering providers, and correlated with test results. Neither the accuracy nor definitive criteria used for TN status reported was independently verified. Results: Incidence of TNBC was reported as 9.7% among non-Ashkenazi patients and 16.5% within the subset with African ancestry. Incidence of TNBC was reported as 4.5% among Ashkenazi patients, but this is likely affected by test ordering for this population. The Table displays the BRCA1/2mutation rates classified by ethnicity and age-group. Conclusions: This study provides the most robust estimate to date of BRCA1/2 mutation prevalence among TNBC patients of all ages. The mutation rates seen among TNBC patients diagnosed after age 60 also illustrate the importance of testing such patients who may not meet the current NCCN HBOC testing criteria. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document